Martek is Granted European Patent on DHA/ARA Oil Blends For Infant Formula and Dietary Supplements

Apr 23, 2001, 01:00 ET from Martek Biosciences Corporation

    COLUMBIA, Md., April 23 /PRNewswire Interactive News Release/ -- Martek
 Biosciences Corporation (Nasdaq: MATK) today announced that the European
 Patent Office ("EPO") has granted European Patent No. EP-B-0 568 606 to the
 Company covering compositions and uses of blends of docosahexaenoic acid (DHA)
 and arachidonic acid (ARA) containing oils as additives or supplements for the
 human diet and infant formula.  The patent covers the blending of DHA from
 microbial or fish oil sources with any microbial source of ARA and the
 inclusion of this blend in infant formula, nutritional supplements and food
 ingredients.  This patent complements others already issued to Martek that
 cover the use of DHA oils and ARA oils individually in infant formulas and
 other products.  Infant formula products with Martek's oils are being marketed
 in over 60 countries around the world by several major manufacturers who have
 obtained licenses to Martek's intellectual property.  This patent is effective
 in 15 European countries with a population of over 350 million.
     "This blends patent is an important addition to the Company's existing DHA
 and ARA patents in Europe," said Henry Linsert, Jr., Martek's Chairman and
 CEO.  "The patent contributes to a growing suite of patents surrounding
 Martek's nutritional oils around the world, and should be of great commercial
 benefit to the Company, especially as it expands its activities in Europe."
     DHA and ARA are fundamental building blocks of the brain.  They are
 naturally delivered to babies through breast milk.  For infant formulas to
 achieve a balance of these essential fatty acids as found in human milk, it is
 important to supplement the formula with a proper blend of both DHA and ARA.
 Martek's oils enable infant formula manufacturers to include both of these
 fatty acids in infant formula in ratios and composition similar to that found
 in human milk.
 
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae. The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns, (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development, and (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
 
     This press release contains forward-looking statements regarding the
 potential value of certain Martek technology.  Such statements involve risks
 and uncertainties that could cause future actual results to differ due to a
 variety of risk factors, including without limitations those factors set forth
 in Exhibit 99.1 to the Company's Form 10-Q for the fiscal quarter ended
 January 31, 2001 and from time to time in the Company's filings with the
 Securities and Exchange Commission.
 
     CONTACT:  Pete Buzy, Chief Financial Officer, of Martek Biosciences
 Corporation, 410-740-0081.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33222917
 
 

SOURCE Martek Biosciences Corporation
    COLUMBIA, Md., April 23 /PRNewswire Interactive News Release/ -- Martek
 Biosciences Corporation (Nasdaq: MATK) today announced that the European
 Patent Office ("EPO") has granted European Patent No. EP-B-0 568 606 to the
 Company covering compositions and uses of blends of docosahexaenoic acid (DHA)
 and arachidonic acid (ARA) containing oils as additives or supplements for the
 human diet and infant formula.  The patent covers the blending of DHA from
 microbial or fish oil sources with any microbial source of ARA and the
 inclusion of this blend in infant formula, nutritional supplements and food
 ingredients.  This patent complements others already issued to Martek that
 cover the use of DHA oils and ARA oils individually in infant formulas and
 other products.  Infant formula products with Martek's oils are being marketed
 in over 60 countries around the world by several major manufacturers who have
 obtained licenses to Martek's intellectual property.  This patent is effective
 in 15 European countries with a population of over 350 million.
     "This blends patent is an important addition to the Company's existing DHA
 and ARA patents in Europe," said Henry Linsert, Jr., Martek's Chairman and
 CEO.  "The patent contributes to a growing suite of patents surrounding
 Martek's nutritional oils around the world, and should be of great commercial
 benefit to the Company, especially as it expands its activities in Europe."
     DHA and ARA are fundamental building blocks of the brain.  They are
 naturally delivered to babies through breast milk.  For infant formulas to
 achieve a balance of these essential fatty acids as found in human milk, it is
 important to supplement the formula with a proper blend of both DHA and ARA.
 Martek's oils enable infant formula manufacturers to include both of these
 fatty acids in infant formula in ratios and composition similar to that found
 in human milk.
 
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae. The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns, (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development, and (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
 
     This press release contains forward-looking statements regarding the
 potential value of certain Martek technology.  Such statements involve risks
 and uncertainties that could cause future actual results to differ due to a
 variety of risk factors, including without limitations those factors set forth
 in Exhibit 99.1 to the Company's Form 10-Q for the fiscal quarter ended
 January 31, 2001 and from time to time in the Company's filings with the
 Securities and Exchange Commission.
 
     CONTACT:  Pete Buzy, Chief Financial Officer, of Martek Biosciences
 Corporation, 410-740-0081.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33222917
 
 SOURCE  Martek Biosciences Corporation